With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
To read the full story
Related Article
- Astellas Completes US$3 Billion Audentes Buyout
January 17, 2020
- Astellas Launches Tender Offer for Audentes
December 17, 2019
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





